Crispr Therapeutics Ag (CRSP) Stock Price, Quote & News

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 561 32 77

Website: www.crisprtx.com

Address:

Baarerstrasse 14, Zug, Switzerland

DarkPooling May. 29 at 6:07 PM

$STG.X $GTLB $UAVS $CRSP listen

0 · Reply

flabb May. 29 at 2:14 PM

$CRSP 54.75 filled

0 · Reply

flabb May. 29 at 1:31 PM

$CRSP 55.72 filled

0 · Reply

Frederick_J_Frenger_Jr May. 28 at 8:07 PM

$CRSP well it didn't tank into the close so that's something...

0 · Reply

DegenStock May. 28 at 6:27 PM

$CRSP few days away from the beginning of the 2H 2026. We should (crossing my fingers) be getting several pipeline updates, hoping we can finally have our bull run

1 · Reply

mikeg1999 May. 28 at 6:07 PM

$CRSP LLY and CRSP in clinic for lipid lowering gene editing. EDIT and Yoltech (chinese biotech) are preclinical for their gene editors. LLY and Yoltech are using base editing for PCSK9 KO, EDIT is using crispr/cas9 for LDL-R upregulation, and CRSP is using crispr/cas9 for ANGPTL3 KO. NYT wrote an article on monday where chief scientist at LLY said (paraphrasing) that these types of gene editing therapies wont be millions of dollars and their goal is primary care setting. very bullish for the space.

0 · Reply

TPopTony May. 28 at 4:43 PM

$CRSP Fox News talked about a new drug and how one shot lowers your LDL over 60% through liver gene therapy. Could it be Crispr’s new drug?

4 · Reply

john_clout_67 May. 28 at 3:32 PM

$TEM $DOCS $CRSP bought these

0 · Reply

Bigfridge_sim May. 28 at 3:24 PM

$CRSP we must be due some significant pipeline / strategic updates to shift us out of this endless range

0 · Reply

Frederick_J_Frenger_Jr May. 28 at 3:10 PM

$CRSP this really is live! All CRSP shareholders are praying right now. LOL!

0 · Reply

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 15, 2026, 8:14 PM EDT - 14 days ago

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

2026-05-13T10:36:49.000Z - 17 days ago

Crispr Therapeutics price target raised to $56 from $50 at Bernstein

May 12, 2026, 4:40 PM EDT - 17 days ago

CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T16:48:13.000Z - 19 days ago

Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI

2026-05-07T08:40:23.000Z - 23 days ago

Crispr Therapeutics price target raised to $82 from $80 at Citi

May 6, 2026, 8:30 AM EDT - 24 days ago

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

2026-05-05T13:15:05.000Z - 25 days ago

Crispr Therapeutics price target lowered to $83 from $86 at BofA

2026-05-04T20:48:53.000Z - 25 days ago

Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)

May 4, 2026, 4:30 PM EDT - 25 days ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 4, 2026, 4:00 PM EDT - 25 days ago

CRISPR Therapeutics AG Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 25 days ago

CRISPR Therapeutics AG Quarterly report: Q1 2026

Apr 27, 2026, 7:06 AM EDT - 4 weeks ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

BEAM NTLA

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 13, 2026, 2:15 PM EDT - 6 weeks ago

CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 1:35 PM EDT - 7 weeks ago

Wall Street Is Completely Wrong About These 5 Stocks

HPQ HUT NVDA RCL

Apr 7, 2026, 8:00 AM EDT - 7 weeks ago

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

2026-03-17T10:56:30.000Z - 2 months ago

Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler

2026-03-13T00:55:12.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today

2026-03-11T11:16:20.000Z - 2 months ago

Crispr Therapeutics prices upsized convertible senior notes offering

Mar 11, 2026, 7:00 AM EDT - 2 months ago

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

2026-03-11T01:05:09.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today

2026-03-10T16:05:15.000Z - 2 months ago

Crispr Therapeutics falls -9.2%

2026-03-10T11:23:21.000Z - 2 months ago

Crispr Therapeutics announces proposed convertible senior notes offering

Mar 10, 2026, 7:00 AM EDT - 2 months ago

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Mar 2, 2026, 11:10 AM EST - 3 months ago

CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T15:40:14.000Z - 3 months ago

Crispr Therapeutics rumor highlighted in Betaville blog

Feb 19, 2026, 12:32 PM EST - 3 months ago

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Feb 18, 2026, 10:45 AM EST - 3 months ago

CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 12, 2026, 4:30 PM EST - 3 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:00 PM EST - 3 months ago

CRISPR Therapeutics AG Annual report: Q4 2025

Feb 12, 2026, 4:00 PM EST - 3 months ago

CRISPR Therapeutics AG Earnings release: Q4 2025

Jan 12, 2026, 11:15 AM EST - 4 months ago

CRISPR Therapeutics AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 4 months ago

CRISPR Therapeutics AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:36 AM EST - 4 months ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 5, 2026, 8:30 AM EST - 5 months ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 8:30 AM EST - 5 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Nov 12, 2025, 11:30 AM EST - 7 months ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 7 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Quarterly report: Q3 2025

Nov 9, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Slides: Corporate presentation

Nov 8, 2025, 10:03 AM EST - 7 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 9:56 AM EST - 7 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Oct 10, 2025, 8:00 AM EDT - 8 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 1, 2025, 8:00 AM EDT - 8 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 9, 2025, 4:00 PM EDT - 9 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 2:22 PM EDT - 9 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

Sep 9, 2025, 8:30 AM EDT - 9 months ago

CRISPR Therapeutics AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:30 PM EDT - 9 months ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 4, 2025, 4:15 PM EDT - 10 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 12:30 PM EDT - 10 months ago

CRISPR Therapeutics AG Quarterly report: Q2 2025

Aug 4, 2025, 12:30 PM EDT - 10 months ago

CRISPR Therapeutics AG Earnings release: Q2 2025

Jul 15, 2025, 12:01 PM EDT - 11 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Jun 26, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 23, 2025, 12:01 PM EDT - 1 year ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Jun 9, 2025, 3:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 12:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 45th Annual William Blair Growth Stock Conference

May 20, 2025, 4:00 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 16, 2025, 7:15 AM EDT - 1 year ago

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

May 7, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Slides: Corporate Presentation

May 6, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q1 2025

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Earnings release: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 8, 2025, 12:45 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Mar 26, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 3, 2025, 10:30 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 4:01 PM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Annual report: Q4 2024

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q4 2024

Feb 5, 2025, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Slides: FY 2025

Jan 8, 2025, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:46 AM EST - 1 year ago

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

NTLA VRTX

Dec 9, 2024, 12:00 PM EST - 1 year ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 20, 2024, 11:00 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 9:01 AM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q3 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q3 2024

Aug 5, 2024, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:00 PM EDT - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 1 year ago

CRISPR Therapeutics AG Earnings release: Q2 2024

Jul 11, 2024, 7:12 AM EDT - 2 years ago

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

ACRS OTLK

Jun 11, 2024, 9:20 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 2:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Jefferies 2024 Global Healthcare Conference

May 24, 2024, 7:40 PM EDT - 2 years ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

May 23, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Slides: FY 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Apr 22, 2024, 4:30 PM EDT - 2 years ago

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 10, 2024, 11:45 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Mar 27, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Mar 13, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Mar 1, 2024, 6:21 PM EST - 2 years ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG

Feb 29, 2024, 5:02 PM EST - 2 years ago

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Feb 26, 2024, 7:02 AM EST - 2 years ago

Is CRISPR Therapeutics the NVIDIA of gene editing?

DarkPooling May. 29 at 6:07 PM

$STG.X $GTLB $UAVS $CRSP listen

0 · Reply

flabb May. 29 at 2:14 PM

$CRSP 54.75 filled

0 · Reply

flabb May. 29 at 1:31 PM

$CRSP 55.72 filled

0 · Reply

Frederick_J_Frenger_Jr May. 28 at 8:07 PM

$CRSP well it didn't tank into the close so that's something...

0 · Reply

DegenStock May. 28 at 6:27 PM

$CRSP few days away from the beginning of the 2H 2026. We should (crossing my fingers) be getting several pipeline updates, hoping we can finally have our bull run

1 · Reply

mikeg1999 May. 28 at 6:07 PM

0 · Reply

TPopTony May. 28 at 4:43 PM

$CRSP Fox News talked about a new drug and how one shot lowers your LDL over 60% through liver gene therapy. Could it be Crispr’s new drug?

4 · Reply

john_clout_67 May. 28 at 3:32 PM

$TEM $DOCS $CRSP bought these

0 · Reply

Bigfridge_sim May. 28 at 3:24 PM

$CRSP we must be due some significant pipeline / strategic updates to shift us out of this endless range

0 · Reply

Frederick_J_Frenger_Jr May. 28 at 3:10 PM

$CRSP this really is live! All CRSP shareholders are praying right now. LOL!

0 · Reply

Bigfridge_sim May. 28 at 2:42 PM

$CRSP

0 · Reply

handmedown1 May. 28 at 1:39 AM

$CRSR $CRSP i saw this up 60% and got excited for a sec. Nope..still dog 💩

0 · Reply

dileep1209 May. 27 at 10:14 PM

$CRSP Cathy investing here from last 9 years Estimated her Average Buy Price: Around $66.00 per share. Current Estimated Total Capital Invested (Cumulative Cost Basis): Approximately $746 million.Current Market Value of the Holding: Around $538 million to $584 million why still stands here patiently ? instead if she reroute this investment into other tickers , she might produced billions

1 · Reply

gabbs May. 27 at 5:03 PM

$CRSP nice.. but would this ever leave the 50's range?

0 · Reply

Frederick_J_Frenger_Jr May. 27 at 3:23 PM

$CRSP no news but I bet they're filling out the paperwork to sell more shares as fast as they can go...

0 · Reply

dens214 May. 27 at 3:01 PM

$CRSP that day has already passed.

0 · Reply

1GreenDay99RedDays May. 27 at 2:16 PM

$EDIT $NTLA $CRSP here it hoes!

0 · Reply

burbs88 May. 27 at 1:56 PM

$CRSP $PRME $EDIT $NTLA All great portfolio diversification stocks against a tech pullback. Big tech has led the market into overbought territory and a fairly steep broader market pullback is inevitable. Money will eventually flow out of these bloated names and into gene editing sector. These stocks can rally against a broader market pullback. A little more positive sector news could go a long way.

0 · Reply

ReadyMate May. 27 at 1:37 PM

$DTIL $BEAM $CRSP $BMRN $CURE So for Gene Therapy companies, this is a breakthrough and yet another validation: "There has never been a treatment that could directly target and eliminate the root source of hepatitis B viral replication and now there is. " $DTIL announces this huge news and as of the market open it's not even visible on Yahoo Finance. -> Data was presented by was presented by Man Fung Yuen MD, Ph.D., Chair Professor of The University of Hong Kong and Li Shu Fan Medical Foundation Professor in Medicine, and the Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, Hong Kong. He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 630 papers in world-renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases and Lancet Oncology. He has delivered more than 360 lectures all over the world.

1 · Reply

AlphaOfBiotech May. 27 at 12:44 PM

$DTIL Revolutionary cure for HBV confirmed $CRSP $ALT $LABU GO GO GO $DTIL Cheers!

0 · Reply

AlphaOfBiotech May. 27 at 12:42 PM

$DTIL This is huge, a very first real cure for HBV and safe, 100% of all patients have a substantial reduction in HbsAg with duration of response for 1 year, 100% patient achieved pgRNA loss GO GO GO $DTIL $CRSP $ALT $LABU 🤑🤑🤑

0 · Reply

Stocks_and_Stacks May. 27 at 4:59 AM

🚀 Bulls grinding higher on Tuesday May 26 with AI/tech momentum and rate-cut optimism! 🐂📈 First off 🤔 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today: selective strength in AI, biotech, and small-cap names powered solid green! $SOUN +18% – SoundHound AI extending its strong run on new voice AI deals. $HIMS +15% – Hims & Hers climbing further on GLP-1 demand and telehealth subscriber beats. $RGTI +27% – Rigetti Computing surging amid quantum computing hype and high-volume buying. $CRSP +21% – CRISPR Therapeutics lifting on gene-editing clinical progress. $PLUG +19% – Plug Power continuing hydrogen energy rotation with positive newsflow. Strong session stacking wins as markets stay resilient, bulls.. keep that momentum rolling into tomorrow! 💪 #TopMovers #BullMarket #Stocks #BangerAlerts #AIRally

1 · Reply

Market Cap	5.44B
Revenue (ttm)	3.51M
Net Income (ttm)	-581.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,569.80%
Debt to Equity Ratio	0.32

Volume	1,932,800
Avg Vol	1,720,490
Day's Range	N/A - N/A
Shares Out	96.45M
Stochastic %K	90%
Beta	1.74
Analysts	Sell
Price Target	$80.71